{
    "title": "115_s23",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Biological Implant Tracking and \nVeteran Safety Act of 2017''.\n\nSEC. 2. IDENTIFICATION AND TRACKING OF BIOLOGICAL IMPLANTS USED IN \n              DEPARTMENT OF VETERANS AFFAIRS MEDICAL FACILITIES.\n\n    (a) In General.--Subchapter II of chapter 73 of title 38, United \nStates Code, is amended by adding at the end the following new section:\n``Sec. 7330B. Identification and tracking of biological implants\n    ``(a) Standard Identification System for Biological Implants.--(1) \nThe Secretary shall adopt the unique device identification system \ndeveloped for medical devices by the Food and Drug Administration under \nsection 519(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n360i(f)), or implement a comparable standard identification system, for \nuse in identifying biological implants intended for use in medical \nprocedures conducted in medical facilities of the Department.\n    ``(2) In adopting or implementing a standard identification system \nfor biological implants under paragraph (1), the Secretary shall permit \na vendor to use any of the accredited entities identified by the Food \nand Drug Administration as an issuing agency pursuant to section \n830.100 of title 21, Code of Federal Regulations, or any successor \nregulation.\n    ``(b) Biological Implant Tracking System.--(1) The Secretary shall \nimplement a system for tracking the biological implants described in \nsubsection (a) from human donor or animal source to implantation.\n    ``(2) The tracking system implemented under paragraph (1) shall be \ncompatible with the identification system adopted or implemented under \nsubsection (a).\n    ``(3) The Secretary shall implement inventory controls compatible \nwith the tracking system implemented under paragraph (1) so that all \npatients who have received, in a medical facility of the Department, a \nbiological implant subject to a recall can be notified of the recall \nif, based on the evaluation by appropriate medical personnel of the \nDepartment of the risks and benefits, the Secretary determines such \nnotification is appropriate.\n    ``(c) Consistency With Food and Drug Administration Regulations.--\nTo the extent that a conflict arises between this section and a \nprovision of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et \nseq.) or sections 351 or 361 of the Public Health Service Act (42 \nU.S.C. 262 and 264) (including any regulations issued under such \nprovisions), the provision of the Federal Food, Drug, and Cosmetic Act \nor Public Health Service Act (including any regulations issued under \nsuch provisions) shall apply.\n    ``(d) Biological Implant Defined.--In this section, the term \n`biological implant' means any human cell, tissue, or cellular or \ntissue-based product or animal product--\n            ``(1) under the meaning given the term `human cells, \n        tissues, or cellular or tissue-based products' in section \n        1271.3 of title 21, Code of Federal Regulations, or any \n        successor regulation; or\n            ``(2) that is regulated as a device under section 201(h) of \n        the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(h)).''.\n    (b) Clerical Amendment.--The table of sections at the beginning of \nsuch chapter is amended by inserting after the item relating to section \n7330A the following new item:\n\n``7330B. Identification and tracking of biological implants.''.\n    (c) Implementation Deadlines.--\n            (1) Standard identification system.--The Secretary of \n        Veterans Affairs shall adopt or implement the standard \n        identification system for biological implants required by \n        subsection (a) of section 7330B of title 38, United States \n        Code, as added by subsection (a), with respect to biological \n        implants described in--\n                    (A) subsection (d)(1) of such section, by not later \n                than the date that is 180 days after the date of the \n                enactment of this Act; and\n                    (B) subsection (d)(2) of such section, in \n                compliance with the compliance dates established by the \n                Food and Drug Administration under section 519(f) of \n                the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n                360i(f)).\n            (2) Tracking system.--The Secretary of Veterans Affairs \n        shall implement the biological implant tracking system required \n        by section 7330B(b) of title 38, United States Code, as added \n        by subsection (a), by not later than the date that is 180 days \n        after the date of the enactment of this Act.\n    (d) Reporting Requirement.--\n            (1) In general.--If the biological implant tracking system \n        required by section 7330B(b) of title 38, United States Code, \n        as added by subsection (a), is not operational by the date that \n        is 180 days after the date of the enactment of this Act, the \n        Secretary of Veterans Affairs shall submit to the Committee on \n        Veterans' Affairs of the Senate and the Committee on Veterans' \n        Affairs of the House of Representatives a written explanation \n        on why the system is not operational for each month until such \n        time as the system is operational.\n            (2) Elements.--Each explanation submitted under paragraph \n        (1) shall include a description of the following:\n                    (A) Each impediment to the implementation of the \n                system described in such paragraph.\n                    (B) Steps being taken to remediate each such \n                impediment.\n                    (C) Target dates for a solution to each such \n                impediment.\n\nSEC. 3. PROCUREMENT OF BIOLOGICAL IMPLANTS USED IN DEPARTMENT OF \n              VETERANS AFFAIRS MEDICAL FACILITIES.\n\n    (a) Procurement.--\n            (1) In general.--Subchapter II of chapter 81 of such title \n        is amended by adding at the end the following new section:\n``Sec. 8129. Procurement of biological implants\n    ``(a) In General.--(1) The Secretary may procure biological \nimplants of human origin only from vendors that meet the following \nconditions:\n            ``(A) The vendor uses the standard identification system \n        adopted or implemented by the Secretary under section 7330B(a) \n        of this title and has safeguards to ensure that a distinct \n        identifier has been in place at each step of distribution of \n        each biological implant from its donor.\n            ``(B) The vendor is registered as required by the Food and \n        Drug Administration under subpart B of part 1271 of title 21, \n        Code of Federal Regulations, or any successor regulation, and \n        in the case of a vendor that uses a tissue distribution \n        intermediary or a tissue processor, the vendor provides \n        assurances that the tissue distribution intermediary or tissue \n        processor is registered as required by the Food and Drug \n        Administration.\n            ``(C) The vendor ensures that donor eligibility \n        determinations and such other records as the Secretary may \n        require accompany each biological implant at all times, \n        regardless of the country of origin of the donor of the \n        biological material.\n            ``(D) The vendor agrees to cooperate with all biological \n        implant recalls conducted on the initiative of the vendor, on \n        the initiative of the original product manufacturer used by the \n        vendor, by the request of the Food and Drug Administration, or \n        by a statutory order of the Food and Drug Administration.\n            ``(E) The vendor agrees to notify the Secretary of any \n        adverse event or reaction report it provides to the Food and \n        Drug Administration, as required by sections 1271.3 and \n        1271.350 of title 21, Code of Federal Regulations, or any \n        successor regulation, or any warning letter from the Food and \n        Drug Administration issued to the vendor or a tissue processor \n        or tissue distribution intermediary used by the vendor by not \n        later than 60 days after the vendor receives such report or \n        warning letter.\n            ``(F) The vendor agrees to retain all records associated \n        with the procurement of a biological implant by the Department \n        for at least 10 years after the date of the procurement of the \n        biological implant.\n            ``(G) The vendor provides assurances that the biological \n        implants provided by the vendor are acquired only from tissue \n        processors that maintain active accreditation with the American \n        Association of Tissue Banks or a similar national accreditation \n        specific to biological implants.\n    ``(2) The Secretary may procure biological implants of non-human \norigin only from vendors that meet the following conditions:\n            ``(A) The vendor uses the standard identification system \n        adopted or implemented by the Secretary under section 7330B(a) \n        of this title.\n            ``(B) The vendor is registered as an establishment as \n        required by the Food and Drug Administration under sections \n        807.20 and 807.40 of title 21, Code of Federal Regulations, or \n        any successor regulation (or is not required to register \n        pursuant to section 807.65(a) of such title, or any successor \n        regulation), and in the case of a vendor that is not the \n        original product manufacturer of such implants, the vendor \n        provides assurances that the original product manufacturer is \n        registered as required by the Food and Drug Administration (or \n        is not required to register).\n            ``(C) The vendor agrees to cooperate with all biological \n        implant recalls conducted on the initiative of the vendor, on \n        the initiative of the original product manufacturer used by the \n        vendor, by the request of the Food and Drug Administration, or \n        by a statutory order of the Food and Drug Administration.\n            ``(D) The vendor agrees to notify the Secretary of any \n        adverse event report it provides to the Food and Drug \n        Administration as required under part 803 of title 21, Code of \n        Federal Regulations, or any successor regulation, or any \n        warning letter from the Food and Drug Administration issued to \n        the vendor or the original product manufacturer used by the \n        vendor by not later than 60 days after the vendor receives such \n        report or warning letter.\n            ``(E) The vendor agrees to retain all records associated \n        with the procurement of a biological implant by the Department \n        for at least 10 years after the date of the procurement of the \n        biological implant.\n    ``(3)(A) The Secretary shall procure biological implants under the \nFederal Supply Schedules of the General Services Administration unless \nsuch implants are not available under such Schedules.\n    ``(B) With respect to biological implants listed on the Federal \nSupply Schedules, the Secretary shall accommodate reasonable vendor \nrequests to undertake outreach efforts to educate medical professionals \nof the Department about the use and efficacy of such biological \nimplants.\n    ``(C) In the case of biological implants that are unavailable for \nprocurement under the Federal Supply Schedules, the Secretary shall \nprocure such implants using competitive procedures in accordance with \napplicable law and the Federal Acquisition Regulation.\n    ``(4) Section 8123 of this title shall not apply to the procurement \nof biological implants.\n    ``(b) Penalties.--In addition to any applicable penalty under any \nother provision of law, any procurement employee of the Department who \nis found responsible for a biological implant procurement transaction \nwith intent to avoid or with reckless disregard of the requirements of \nthis section shall be ineligible to hold a certificate of appointment \nas a contracting officer or to serve as the representative of an \nordering officer, contracting officer, or purchase card holder.\n    ``(c) Definitions.--In this section:\n            ``(1) The term `biological implant' has the meaning given \n        such term in section 7330B(d) of this title.\n            ``(2) The term `distinct identifier' means a distinct \n        identification code that--\n                    ``(A) relates a biological implant to the human \n                donor of the implant and to all records pertaining to \n                the implant;\n                    ``(B) includes information designed to facilitate \n                effective tracking, using the distinct identification \n                code, from the donor to the recipient and from the \n                recipient to the donor; and\n                    ``(C) satisfies the requirements of section \n                1271.290(c) of title 21, Code of Federal Regulations, \n                or any successor regulation.\n            ``(3) The term `tissue distribution intermediary' means an \n        agency that acquires and stores human tissue for further \n        distribution and performs no other tissue banking functions.\n            ``(4) The term `tissue processor' means an entity \n        processing human tissue for use in biological implants, \n        including activities performed on tissue other than donor \n        screening, donor testing, tissue recovery and collection \n        functions, storage, or distribution.''.\n            (2) Clerical amendment.--The table of sections at the \n        beginning of such chapter is amended by inserting after the \n        item relating to section 8128 the following new item:\n\n``8129. Procurement of biological implants.''.\n    (b) Effective Date.--Section 8129 of title 38, United States Code, \nas added by subsection (a), shall take effect on the date that is 180 \ndays after the date on which the tracking system required under section \n7330B(b) of such title, as added by section 2(a), is implemented.\n    (c) Special Rule for Cryopreserved Products.--During the three-year \nperiod beginning on the effective date of section 8129 of title 38, \nUnited States Code, as added by subsection (a), biological implants \nproduced and labeled before that effective date may be procured by the \nDepartment of Veterans Affairs without relabeling under the standard \nidentification system adopted or implemented under section 7330B of \nsuch title, as added by section 2(a)."
}